Yamamoto K, Shen B, Zarins C, Scanu A M
Arteriosclerosis. 1984 Jul-Aug;4(4):418-34. doi: 10.1161/01.atv.4.4.418.
Triton WR-1339 was incubated in vitro in various proportions with plasma from normolipidemic rhesus monkeys or with ultracentrifugally purified lipoproteins, and the products were examined by isopycnic density gradient ultracentrifugation, agarose column chromatography, electrophoretic and immunochemical techniques, and electron microscopy. Some experiments used apo A-I, apo A-II, or Triton labeled with either 125I or 131I. At concentrations of less than 10 mg/ml plasma, Triton interacted preferentially with HDL, changing lipoprotein size and density; Triton was progressively incorporated into the HDL particles, displacing apo E, apo A-I, and apo A-II. At concentrations above 10 mg/ml plasma, Triton displaced all apo A-I from the particle, and much lipid was dissolved into the Triton micelles. When Triton-treated HDL particles were used as a substrate for the enzyme LCAT, enzyme activity decreased in parallel to the displacement of apo A-I. There was no displacement of apo B from LDL nor any loss of lipids; but the particles became deformed and formed rouleaux. A single intravenous dose of Triton WR-1339 administered to a normolipidemic monkey (N) and to a hypercholesterolemic monkey (H) resulted in concentration-dependent HDL changes similar to those observed in vitro. LDL was less affected by Triton, with changes occurring only at high doses. After these structural changes, intravenously injected 131I apo A-I disappeared rapidly from the circulation; 125I apo A-II disappeared less rapidly. These increased clearances were accompanied by a drop in apo A-I plasma levels and the disappearance of HDL particles from plasma. The lipoprotein and apolipoprotein patterns returned to normal 14 days after Triton. We conclude that Triton WR-1339, when exposed to rhesus plasma in vitro or in vivo, interacts preferentially with HDL in a dose-dependent manner. At low concentrations, Triton acts on surface components of the HDL particle; at higher concentrations, Triton penetrates the particle, causing structural disruption. Because of its high affinity for HDL, Triton WR-1339 is a useful reagent for study of HDL structure-function relationships.
将Triton WR - 1339与正常血脂的恒河猴血浆或超速离心纯化的脂蛋白按不同比例进行体外孵育,然后通过等密度梯度超速离心、琼脂糖柱色谱、电泳和免疫化学技术以及电子显微镜对产物进行检测。一些实验使用了用125I或131I标记的载脂蛋白A - I、载脂蛋白A - II或Triton。在血浆浓度低于10mg/ml时,Triton优先与高密度脂蛋白(HDL)相互作用,改变脂蛋白的大小和密度;Triton逐渐掺入HDL颗粒中,取代载脂蛋白E、载脂蛋白A - I和载脂蛋白A - II。在血浆浓度高于10mg/ml时,Triton将颗粒中的所有载脂蛋白A - I取代,并且大量脂质溶解到Triton微团中。当用经Triton处理的HDL颗粒作为卵磷脂胆固醇酰基转移酶(LCAT)的底物时,酶活性随着载脂蛋白A - I的取代而平行下降。低密度脂蛋白(LDL)中的载脂蛋白B没有被取代,脂质也没有损失;但是颗粒发生变形并形成缗钱状。给一只正常血脂的猴子(N)和一只高胆固醇血症的猴子(H)单次静脉注射Triton WR - 1339,导致HDL出现与体外观察到的类似的浓度依赖性变化。LDL受Triton的影响较小,仅在高剂量时才会发生变化。在这些结构变化之后,静脉注射的131I标记的载脂蛋白A - I迅速从循环中消失;125I标记的载脂蛋白A - II消失得较慢。这些清除率的增加伴随着血浆中载脂蛋白A - I水平的下降以及HDL颗粒从血浆中的消失。在注射Triton 14天后,脂蛋白和载脂蛋白模式恢复正常。我们得出结论,Triton WR - 1339在体外或体内与恒河猴血浆接触时,以剂量依赖性方式优先与HDL相互作用。在低浓度时,Triton作用于HDL颗粒的表面成分;在较高浓度时,Triton穿透颗粒,导致结构破坏。由于其对HDL具有高亲和力,Triton WR - 1339是研究HDL结构 - 功能关系的有用试剂。